What Is It?
A triple receptor agonist — GLP-1, GIP, and glucagon simultaneously. Phase 3 trial results published December 2025. FDA approval projected for 2027. The most potent weight management compound in clinical development.
How Does It Work?
Semaglutide turns down one dial (GLP-1 — appetite). Tirzepatide turns down two (GLP-1 + GIP). Retatrutide turns down three. GLP-1 suppresses appetite. GIP reduces fat storage. Glucagon accelerates fat burning. First drug to activate all three pathways at once.
Primary Benefits (research suggests)
- 28.7% average weight loss in Phase 3 (~71 lbs average)
- 82% liver fat reduction
- 72% of pre-diabetic participants reverted to normal blood sugar
- 75.8% osteoarthritis pain reduction
Run the Numbers
Calculate your Retatrutide reconstitution — BAC water volume, syringe units, and draw amounts. Free, no login required.
Open the Calculator →The Honest Part
- Not FDA-approved yet (projected 2027).
- Has side effects — GI issues are common during titration.
- Research compound versions may differ from pharmaceutical formulations.
- Not for self-sourcing.
- For research and educational purposes only.
Track Retatrutide in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →